DE69533942D1 - Behandlung von lösungen roter blutkörperchen mit antiviralen wirkstoffen - Google Patents
Behandlung von lösungen roter blutkörperchen mit antiviralen wirkstoffenInfo
- Publication number
- DE69533942D1 DE69533942D1 DE69533942T DE69533942T DE69533942D1 DE 69533942 D1 DE69533942 D1 DE 69533942D1 DE 69533942 T DE69533942 T DE 69533942T DE 69533942 T DE69533942 T DE 69533942T DE 69533942 D1 DE69533942 D1 DE 69533942D1
- Authority
- DE
- Germany
- Prior art keywords
- solutions
- treatment
- red blood
- active substances
- methods
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/16—Blood plasma; Blood serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
- A61L2/0082—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using chemical substances
- A61L2/0088—Liquid substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/16—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using chemical substances
- A61L2/18—Liquid substances or solutions comprising solids or dissolved gases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D219/00—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
- C07D219/04—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
- C07D219/08—Nitrogen atoms
- C07D219/10—Nitrogen atoms attached in position 9
- C07D219/12—Amino-alkylamino radicals attached in position 9
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/04—Inactivation or attenuation; Producing viral sub-units
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10161—Methods of inactivation or attenuation
- C12N2730/10163—Methods of inactivation or attenuation by chemical treatment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16061—Methods of inactivation or attenuation
- C12N2740/16063—Methods of inactivation or attenuation by chemical treatment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/18011—Details ssRNA Bacteriophages positive-sense
- C12N2795/18111—Leviviridae
- C12N2795/18161—Methods of inactivation or attenuation
- C12N2795/18163—Methods of inactivation or attenuation by chemical treatment
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/338,040 US5691132A (en) | 1994-11-14 | 1994-11-14 | Method for inactivating pathogens in red cell compositions using quinacrine mustard |
US338040 | 1994-11-14 | ||
PCT/US1995/014550 WO1996014737A1 (en) | 1994-11-14 | 1995-11-08 | Treating red blood cell solutions with anti-viral agents |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69533942D1 true DE69533942D1 (de) | 2005-02-24 |
DE69533942T2 DE69533942T2 (de) | 2005-12-29 |
Family
ID=23323153
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69533942T Expired - Lifetime DE69533942T2 (de) | 1994-11-14 | 1995-11-08 | Behandlung von lösungen roter blutkörperchen mit antiviralen wirkstoffen |
Country Status (8)
Country | Link |
---|---|
US (6) | US5691132A (de) |
EP (1) | EP0804074B1 (de) |
JP (1) | JP3145124B2 (de) |
AT (1) | ATE287210T1 (de) |
AU (1) | AU712034B2 (de) |
CA (1) | CA2203885C (de) |
DE (1) | DE69533942T2 (de) |
WO (1) | WO1996014737A1 (de) |
Families Citing this family (84)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU4107396A (en) | 1992-03-02 | 1996-06-06 | Cerus Corporation | Synthetic media for blood components |
US5691132A (en) * | 1994-11-14 | 1997-11-25 | Cerus Corporation | Method for inactivating pathogens in red cell compositions using quinacrine mustard |
DE4444045C2 (de) * | 1994-12-10 | 1997-04-17 | Behringwerke Ag | Verfahren zur Inaktivierung von Viren mit Hilfe von Acridin oder Acridinderivaten |
US6544727B1 (en) | 1995-06-07 | 2003-04-08 | Cerus Corporation | Methods and devices for the removal of psoralens from blood products |
US20040048235A1 (en) * | 1995-08-29 | 2004-03-11 | V.I. Technologies, Inc. | Methods and compositions for the selective modification of nucleic acids |
US6136586A (en) * | 1995-08-29 | 2000-10-24 | Vi Technologies, Inc. | Methods for the selective modification of viral nucleic acids |
US20040053208A1 (en) * | 1995-08-29 | 2004-03-18 | V. I. TECHNOLOGIES, Inc. | Methods to selectively inactivate parasites in biological compositions |
FR2753536B1 (fr) * | 1996-09-16 | 1998-11-20 | Aetsrn | Procede d'evaluation de la phagocytose de cellules cibles par des macrophages in vitro ; applications diagnostiques et application au controle de qualite de stocks de cellules |
US6190609B1 (en) | 1996-11-19 | 2001-02-20 | Baxter International Inc. | Methods and apparatus for inactivating contaminants in biological fluid |
US5922278A (en) * | 1996-11-19 | 1999-07-13 | Baxter International Inc. | Method and apparatus for inactivating contaminants in biological fluid |
WO1998030545A1 (en) * | 1997-01-06 | 1998-07-16 | Cerus Corporation | Frangible compounds for pathogen inactivation |
US6514987B1 (en) * | 1997-01-06 | 2003-02-04 | Cerus Corporation | Frangible compounds for pathogen inactivation |
US6093725A (en) * | 1997-01-06 | 2000-07-25 | Cerus Corporation | Frangible compounds for pathogen inactivation |
EP1364944A1 (de) * | 1997-01-06 | 2003-11-26 | Cerus Corporation | Verbindungen mit leicht spaltbaren Bindungen zur Inaktivierung von Pathogenen |
US20010018179A1 (en) | 1998-01-06 | 2001-08-30 | Derek J. Hei | Batch devices for the reduction of compounds from biological compositions containing cells and methods of use |
US20010009756A1 (en) | 1998-01-06 | 2001-07-26 | Derek Hei | Flow devices for the reduction of compounds from biological compositions and methods of use |
US6093564A (en) * | 1997-10-03 | 2000-07-25 | V.I. Technologies, Inc. | Methods and compositions for the selective modification of nucleic acids |
US6352695B1 (en) | 1997-10-03 | 2002-03-05 | V.I. Technologies, Inc. | Methods and compositions for the selective modification of nucleic acids |
EP1032265B1 (de) * | 1997-11-20 | 2003-10-29 | Cerus Corporation | Neue psoralene zur inaktivierung von pathogenen |
AU745209B2 (en) * | 1998-01-06 | 2002-03-14 | Cerus Corporation | Methods for quenching pathogen inactivators in biological materials |
US7611831B2 (en) * | 1998-01-06 | 2009-11-03 | Cerus Corporation | Adsorbing pathogen-inactivating compounds with porous particles immobilized in a matrix |
US6369048B1 (en) | 1998-01-12 | 2002-04-09 | V.I. Technologies, Inc. | Methods and compositions for inactivating viruses |
CA2332314A1 (en) | 1998-06-11 | 1999-12-16 | Cerus Corporation | Use of alkylating compounds for inhibiting proliferation of arterial smooth muscle cells |
US6908553B1 (en) | 1998-07-08 | 2005-06-21 | Baxter International Inc. | Composite membrane with particulate matter substantially immobilized therein |
US6099734A (en) * | 1998-07-08 | 2000-08-08 | Baxter International Inc. | Apparatus, membranes and methods for removing organic compounds from a biological fluid |
US6277337B1 (en) | 1998-07-21 | 2001-08-21 | Gambro, Inc. | Method and apparatus for inactivation of biological contaminants using photosensitizers |
US20070099170A1 (en) * | 1998-07-21 | 2007-05-03 | Navigant Biotechnologies, Inc. | Method for treatment and storage of blood and blood products using endogenous alloxazines and acetate |
US6258577B1 (en) | 1998-07-21 | 2001-07-10 | Gambro, Inc. | Method and apparatus for inactivation of biological contaminants using endogenous alloxazine or isoalloxazine photosensitizers |
US6617100B2 (en) | 1998-09-25 | 2003-09-09 | V.I. Technologies, Inc. | Solid phase quenching systems |
US6403359B1 (en) | 1998-09-25 | 2002-06-11 | V. I. TECHNOLOGIES, Inc. | Solid phase quenching systems |
US6150109A (en) | 1999-01-25 | 2000-11-21 | V. I. TECHNOLOGIES, Inc. | Lipophilic quenching of viral inactivating agents |
US7025877B1 (en) | 1999-06-03 | 2006-04-11 | Baxter International Inc. | Processing set for processing and treating a biological fluid |
US7445756B2 (en) | 1999-06-03 | 2008-11-04 | Fenwal, Inc. | Fluid processing sets and organizers for the same |
US7068361B2 (en) | 1999-06-03 | 2006-06-27 | Baxter International | Apparatus, systems and methods for processing and treating a biological fluid with light |
US6565802B1 (en) | 1999-06-03 | 2003-05-20 | Baxter International Inc. | Apparatus, systems and methods for processing and treating a biological fluid with light |
US6268120B1 (en) | 1999-10-19 | 2001-07-31 | Gambro, Inc. | Isoalloxazine derivatives to neutralize biological contaminants |
TW590780B (en) | 2000-06-02 | 2004-06-11 | Gambro Inc | Additive solutions containing riboflavin |
US7648699B2 (en) | 2000-06-02 | 2010-01-19 | Caridianbct Biotechnologies, Llc | Preventing transfusion related complications in a recipient of a blood transfusion |
US7985588B2 (en) | 2000-06-02 | 2011-07-26 | Caridianbct Biotechnologies, Llc | Induction of and maintenance of nucleic acid damage in pathogens using riboflavin and light |
US9044523B2 (en) | 2000-06-15 | 2015-06-02 | Terumo Bct, Inc. | Reduction of contaminants in blood and blood products using photosensitizers and peak wavelengths of light |
AU2002211795C1 (en) * | 2000-10-17 | 2008-04-17 | Zeptometrix Corporation | Nucleic acid amplification controls |
DE10051628B4 (de) * | 2000-10-18 | 2007-06-06 | Fresenius Hemocare Beteiligungs Gmbh | Einzelsträngiges Oligonukleotid und dessen Verwendung |
US6548241B1 (en) * | 2000-11-28 | 2003-04-15 | Gambro, Inc. | Storage solution containing photosensitizer for inactivation of biological contaminants |
CA2434256A1 (en) * | 2000-12-21 | 2003-07-31 | David Cook | Methods for inactivation of pathogens in biological materials |
US20020131958A1 (en) * | 2001-01-22 | 2002-09-19 | John Chapman | Method for purifying a biological composition |
US7381976B2 (en) | 2001-03-13 | 2008-06-03 | Triton Thalassic Technologies, Inc. | Monochromatic fluid treatment systems |
US20030031584A1 (en) * | 2001-08-10 | 2003-02-13 | Wilson Burgess | Methods for sterilizing biological materials using dipeptide stabilizers |
US7235392B2 (en) * | 2001-12-07 | 2007-06-26 | The Ohio State University Research Foundation | Apoptotic EBV-transformed lymphocytes, a therapeutic agent for post-transplant lymphoproliferative disorder |
US7745180B2 (en) * | 2002-04-24 | 2010-06-29 | Hitachi Chemical Co., Ltd. | Device and method for high-throughput quantification of mRNA from whole blood |
EP1531823A4 (de) | 2002-05-10 | 2007-07-18 | Univ Ohio State | Flavin n-oxide: neue krebsmittel und mittel zur beseitigung von erregern |
US20090110702A1 (en) * | 2002-07-12 | 2009-04-30 | The Johns Hopkins University | Mesothelin Vaccines and Model Systems and Control of Tumors |
US9200036B2 (en) | 2002-07-12 | 2015-12-01 | The Johns Hopkins University | Mesothelin vaccines and model systems |
CA2492160A1 (en) * | 2002-07-12 | 2004-01-22 | The Johns Hopkins University | Mesothelin vaccines and model systems |
AU2003272491B2 (en) * | 2002-09-18 | 2008-10-02 | The Trustees Of The University Of Pennsylvania | Compositions, methods and kits for detection of an antigen on a cell and in a biological mixture |
CA2515298C (en) * | 2003-02-06 | 2014-04-08 | Cerus Corporation | Modified free-living microbes, vaccine compositions and methods of use thereof |
US7695725B2 (en) | 2003-02-06 | 2010-04-13 | Aduro Biotech | Modified free-living microbes, vaccine compositions and methods of use thereof |
EP1592441B1 (de) * | 2003-02-06 | 2012-04-11 | Aduro Biotech | Listerien deren eindringen in nicht-phagozytische zellen abgeschwächt ist, impfstoffe, die diese listerien enthalten und deren verwendungen |
US7534348B2 (en) * | 2003-09-12 | 2009-05-19 | Fenwal, Inc. | Flow-through removal device and system using such device |
US20050137517A1 (en) | 2003-12-19 | 2005-06-23 | Baxter International Inc. | Processing systems and methods for providing leukocyte-reduced blood components conditioned for pathogen inactivation |
US7842289B2 (en) * | 2003-12-24 | 2010-11-30 | Aduro Biotech | Recombinant nucleic acid molecules, expression cassettes, and bacteria, and methods of use thereof |
US20120225044A9 (en) * | 2004-09-07 | 2012-09-06 | Zymequest, Inc. | Compositions and methods for prolonging survival of platelets |
CA2621250A1 (en) * | 2004-09-07 | 2006-03-16 | Zymequest, Inc. | Apparatus for prolonging survival of platelets |
BRPI0518198B8 (pt) * | 2004-10-29 | 2021-06-22 | Cerus Corp | método ex vivo para tratar uma composição de células hemácias para inativar um patógeno, se presente, bem como composição e kit |
DE102007038513A1 (de) | 2007-08-16 | 2009-02-19 | Robert Bosch Gmbh | Monostatischer Mehrstrahlradarsensor für Kraftfahrzeuge |
US9318248B2 (en) | 2007-10-25 | 2016-04-19 | Iii Holdings 2, Llc | Spin valve element and method of manufacturing same |
KR101742533B1 (ko) | 2008-04-09 | 2017-06-01 | 세루스 코포레이션 | 적혈구 병원체 불활성화를 위한 개선된 퀀칭 방법 |
JP2011523553A (ja) | 2008-05-19 | 2011-08-18 | アデュロ バイオテック | PrfA*変異株リステリアを含む組成物およびその使用法 |
WO2010107789A1 (en) * | 2009-03-17 | 2010-09-23 | Marv Enterprises Llc | Sequential extracorporeal treatment of bodily fluids |
EP3834851A1 (de) * | 2010-12-30 | 2021-06-16 | Laboratoire Français du Fractionnement et des Biotechnologies | Glykole als pathogeninaktivierungsstoffe |
WO2013148405A2 (en) * | 2012-03-27 | 2013-10-03 | Felder Mitchell S | Treatment for atherosclerosis |
JP6268167B2 (ja) | 2012-05-31 | 2018-01-24 | エイジェンシー フォー サイエンス,テクノロジー アンド リサーチ | タンパク質製剤中の凝集物含量を低減するために混合型多官能表面を使用する方法 |
JP6297029B2 (ja) | 2012-05-31 | 2018-03-20 | エイジェンシー・フォー・サイエンス,テクノロジー・アンド・リサーチ | 多様な官能基を有する粒子による免疫グロブリンg調製物のクロマトグラフィー精製 |
SG11201407812SA (en) | 2012-05-31 | 2014-12-30 | Agency Science Tech & Res | Methods for reducing levels of protein-contaminant complexes and aggregates in protein preparations by treatment with electropositive organic additives |
WO2014123484A1 (en) | 2013-02-06 | 2014-08-14 | Agency For Science, Technology And Research | Methods For Reducing Aggregate Content In Protein Preparations |
EP3194576B1 (de) | 2014-07-23 | 2020-11-18 | Cerus Corporation | Verfahren zur herstellung von thrombozyten-produkten |
DE202015100806U1 (de) | 2015-02-19 | 2015-04-15 | Paul Schaffrath | Vorrichtung zur Inaktivierung von Krankheitserregern in Flüssigkeiten |
CN108135936A (zh) | 2015-06-26 | 2018-06-08 | 塞鲁斯公司 | 冷沉淀物组合物及其制备方法 |
US10799533B2 (en) | 2015-10-23 | 2020-10-13 | Cerus Corporation | Plasma compositions and methods of use thereof |
EA201991506A1 (ru) | 2016-12-23 | 2020-01-23 | Сирус Корпорейшн | Системы и способы для тестирования и скрининга с использованием связанных с соединениями субстратов |
EP3562493A1 (de) | 2016-12-31 | 2019-11-06 | Cerus Corporation | Zusammensetzungen und verfahren zur herstellung von erythrozyten |
US11235090B2 (en) | 2017-03-03 | 2022-02-01 | Cerus Corporation | Kits and methods for preparing pathogen-inactivated platelet compositions |
AU2018395525B2 (en) | 2017-12-29 | 2023-09-14 | Cerus Corporation | Systems and methods for treating biological fluids |
MX2021003180A (es) | 2018-09-20 | 2021-05-14 | Cerus Corp | Métodos y kits para preparar sangre entera con inactivación de patógenos. |
WO2020264421A1 (en) | 2019-06-28 | 2020-12-30 | Cerus Corporation | System and methods for implementing a biological fluid treatment device |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE444045C (de) | 1925-10-20 | 1927-05-13 | Ernst Kaempfer | Verfahren zur Herstellung von Schweissdraht |
US3819270A (en) * | 1972-10-02 | 1974-06-25 | Block Engineering | Blood cell analyzer |
US4196281A (en) * | 1976-10-20 | 1980-04-01 | Regents Of The University Of California | Psoralens |
US4124598A (en) * | 1976-10-20 | 1978-11-07 | Hoffmann-La Roche Inc. | Psoralens |
US4182750A (en) * | 1977-04-21 | 1980-01-08 | Sullivan Thomas E | Bloodcompatible functional polymers |
US4107182A (en) * | 1977-07-29 | 1978-08-15 | Hoffmann-La Roche Inc. | 7-Oxo-9-methoxy-7H-furo[3,2-g][1]benzopyran-6-carboxylic acid |
US4252653A (en) * | 1978-08-25 | 1981-02-24 | Stolle Research And Development Corporation | Hemoperfusion device for specific modification or removal of components of whole blood |
US4269851A (en) * | 1979-09-10 | 1981-05-26 | Thomas C. Elder, Inc. | 8-Aminoalkyl-4-alkylpsoralens |
US4269852A (en) | 1979-09-10 | 1981-05-26 | Thomas C. Elder, Inc. | 4'-Substituted-4,5',8-trialkylpsoralens |
US4370344A (en) * | 1979-09-10 | 1983-01-25 | Elder Pharmaceuticals, Inc. | 5'-Aminoalkyl-4'-alkylpsoralens |
US4298614A (en) | 1979-09-10 | 1981-11-03 | Thomas C. Elder, Inc. | 5'-Aminoalkyl-4',4-dialkylpsoralens |
US4294822A (en) | 1980-07-29 | 1981-10-13 | Thomas C. Elder, Inc. | 5-Aminoalkyl-4,4,8-trialkylpsoralens |
US4613322A (en) * | 1982-12-08 | 1986-09-23 | Edelson Richard Leslie | Method and system for externally treating the blood |
US4748120A (en) * | 1983-05-02 | 1988-05-31 | Diamond Scientific Co. | Photochemical decontamination treatment of whole blood or blood components |
US4727027A (en) * | 1983-05-02 | 1988-02-23 | Diamond Scientific Co. | Photochemical decontamination treatment of whole blood or blood components |
IT1169415B (it) * | 1983-05-09 | 1987-05-27 | Jean Jacques Goupil | Prodotti medicinali contenenti un derivato del psoralene |
US4683202A (en) * | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4683195A (en) * | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4704352A (en) | 1985-06-25 | 1987-11-03 | Baxter Travenol Laboratories, Inc. | L-ascorbate-2-phosphate salts in blood cell storage |
US5055485A (en) | 1988-12-02 | 1991-10-08 | New York Blood Center, Inc. | Inactivation of viruses in cell- and protein-containing compositions using aryl diol epoxides |
US5356929A (en) * | 1989-01-23 | 1994-10-18 | Lehigh University | Reduced and quaternized psoralens as photo-activated therapeutics |
US5342752A (en) | 1990-04-16 | 1994-08-30 | Cryopharm Corporation | Method of inactivation of viral blood contaminants using acridine deriatives |
US5691371A (en) | 1993-05-25 | 1997-11-25 | Auckland Uniservices Limited | Nitrobenzyl mustard quaternary salts and their use as hypoxia-selective cytotoxic agents |
US5399719A (en) * | 1993-06-28 | 1995-03-21 | Steritech, Inc. | Compounds for the photodecontamination of pathogens in blood |
AU1565895A (en) | 1994-01-10 | 1995-08-01 | Hemasure, Inc. | Inactivation of viruses present in blood components using chemically-activated compounds |
US5691132A (en) * | 1994-11-14 | 1997-11-25 | Cerus Corporation | Method for inactivating pathogens in red cell compositions using quinacrine mustard |
DE4444045C2 (de) | 1994-12-10 | 1997-04-17 | Behringwerke Ag | Verfahren zur Inaktivierung von Viren mit Hilfe von Acridin oder Acridinderivaten |
US6177441B1 (en) * | 1995-06-05 | 2001-01-23 | Cerus Corporation | Treating red blood cell solutions with anti-viral agents |
EP0773716A4 (de) * | 1995-06-07 | 1999-08-04 | Cerus Corp | Behandlung von lösungen roter blutkörperchen mit antivralen wirkstoffen |
AU7717396A (en) | 1995-06-29 | 1997-02-05 | Hemasure, Inc. | Inactivation of pathogens using hydroxymethylamines |
US6114108A (en) * | 1995-08-29 | 2000-09-05 | V.I. Technologies, Inc. | Methods and compositions for the selective modification of viral nucleic acids |
US6136586A (en) | 1995-08-29 | 2000-10-24 | Vi Technologies, Inc. | Methods for the selective modification of viral nucleic acids |
US6093725A (en) * | 1997-01-06 | 2000-07-25 | Cerus Corporation | Frangible compounds for pathogen inactivation |
US5891705A (en) | 1997-04-08 | 1999-04-06 | Pentose Pharmaceuticals, Inc. | Method for inactivating a virus |
US6093564A (en) | 1997-10-03 | 2000-07-25 | V.I. Technologies, Inc. | Methods and compositions for the selective modification of nucleic acids |
US6150109A (en) | 1999-01-25 | 2000-11-21 | V. I. TECHNOLOGIES, Inc. | Lipophilic quenching of viral inactivating agents |
-
1994
- 1994-11-14 US US08/338,040 patent/US5691132A/en not_active Expired - Fee Related
-
1995
- 1995-06-05 US US08/464,471 patent/US5559250A/en not_active Expired - Fee Related
- 1995-06-07 US US08/486,821 patent/US6171777B1/en not_active Expired - Fee Related
- 1995-06-07 US US08/476,842 patent/US6143490A/en not_active Expired - Lifetime
- 1995-11-08 WO PCT/US1995/014550 patent/WO1996014737A1/en active IP Right Grant
- 1995-11-08 CA CA002203885A patent/CA2203885C/en not_active Expired - Lifetime
- 1995-11-08 AT AT95939848T patent/ATE287210T1/de not_active IP Right Cessation
- 1995-11-08 JP JP51618996A patent/JP3145124B2/ja not_active Expired - Lifetime
- 1995-11-08 EP EP95939848A patent/EP0804074B1/de not_active Expired - Lifetime
- 1995-11-08 AU AU41513/96A patent/AU712034B2/en not_active Ceased
- 1995-11-08 DE DE69533942T patent/DE69533942T2/de not_active Expired - Lifetime
-
2000
- 2000-03-30 US US09/539,226 patent/US6410219B1/en not_active Expired - Fee Related
-
2002
- 2002-03-12 US US10/096,196 patent/US20020182581A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JPH10507367A (ja) | 1998-07-21 |
EP0804074B1 (de) | 2005-01-19 |
US5559250A (en) | 1996-09-24 |
AU4151396A (en) | 1996-06-06 |
JP3145124B2 (ja) | 2001-03-12 |
ATE287210T1 (de) | 2005-02-15 |
US5691132A (en) | 1997-11-25 |
CA2203885A1 (en) | 1996-05-23 |
WO1996014737A1 (en) | 1996-05-23 |
DE69533942T2 (de) | 2005-12-29 |
CA2203885C (en) | 2007-01-09 |
US20020182581A1 (en) | 2002-12-05 |
EP0804074A4 (de) | 1999-12-08 |
US6171777B1 (en) | 2001-01-09 |
US6410219B1 (en) | 2002-06-25 |
EP0804074A1 (de) | 1997-11-05 |
US6143490A (en) | 2000-11-07 |
AU712034B2 (en) | 1999-10-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69533942D1 (de) | Behandlung von lösungen roter blutkörperchen mit antiviralen wirkstoffen | |
ATE243198T1 (de) | Verbindungen mit leicht spaltbaren bindungen zur inaktivierung von pathogenen | |
DE19775096I2 (de) | Desulfatohirudine Verfahren zu ihrer Herstellung und pharmazeutische Mittel | |
ATE373092T1 (de) | Zusammensetzungen und verfahren zur behandlung von chlamydia-infektionen | |
DE69328685T2 (de) | Verfahren zur inaktivierung von bakterien in blutpräparaten mit hilfe von methoxypsoralen | |
ATE191567T1 (de) | Bestimmung von nukleären matrixproteinen in flüssigkeiten | |
DE3783282D1 (de) | Varianten von lav-viren, deren dns- und proteinkomponenten und deren verwendung, insbesondere zu diagnostischen zwecken und zur herstellung von immunogenen zusammensetzungen. | |
DE3886254D1 (de) | Apparat zur Behandlung von biologischen Proben und Behandlungsmethoden mit dem Apparat. | |
DE58904683D1 (de) | Praeparat mit antikoerperaktivitaet und breitem wirkungsspektrum, daraus bestehende oder diese enthaltende mittel und deren verwendung zur behandlung von bakteriell oder toxin-bedingten erkrankungen und zur bekaempfung von protozoen. | |
ES2168361T3 (es) | Secuencias de adn para metaloproteasas de la matriz, su preparacion y empleo. | |
ATE200990T1 (de) | Vorrichtung zur untersuchung von biologischen und medizinischen proben | |
ATE5749T1 (de) | Verfahren und diagnostisches mittel zur direkten bestimmung des lipidgehaltes der betalipoproteine des blutes. | |
ATE108906T1 (de) | Methode zur bestimmung des verhaltens von medikamenten in lebewesen. | |
DE58903378D1 (de) | Traegergebundenes mehrkomponentiges nachweissystem zur kolorimetrischen bestimmung esterolytisch oder/und proteolytisch aktiver inhaltsstoffe von koerperfluessigkeiten. | |
FI971879A0 (fi) | Allogeenisten ja ksenogeenisten proteiinien vasta-aineet, niiden käyttö diagnoosissa ja hoidossa ja menetelmät niiden määrittämiseksi | |
RU2202363C2 (ru) | Способ определения чувствительности живого организма и/или его клеток к воздействию вещества, поля или комбинации веществ и/или полей | |
JPS6368527A (ja) | Hb抗原不活化剤 | |
Gruber et al. | Experience of using a B. licheniformis plate for a better detection of sulphonamides with the biological inhibitor test. | |
UA33564A (uk) | Спосіб підготовки проб біорідин для визначення вмісту речовин ліпідної природи | |
DE3776662D1 (de) | Pharmazeutische zusammensetzungen zur behandlung von hyperproliferativer hautkrankheit. | |
DE68914989T2 (de) | Verfahren zur Behandlung und Entfärbung von Proteinlösungen, die Häm- und Chlorophyll-Pigmente enthalten, und entsprechende Produkte. | |
NO871150D0 (no) | Innretning for spesifikk, kvantitativ bestemmelse av proteiner og andre komponenter i blod og andre vaesker. | |
ATE104829T1 (de) | Verfahren zur behandlung und entfaerbung von proteinloesungen, die haem- und chlorophyllpigmente enthalten, und entsprechende produkte. | |
RU94022192A (ru) | Основа лекарственного средства | |
RU94026025A (ru) | Способ диагностики красного волосяного лишая девержи |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |